Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive β-lapachone on cancer cells

Neoplasia

Volumn 9, Issue 8, 2007, Pages 634-642

  Choi, Eun K ^a   Terai, Kaoru ^b   Ji, In Mi ^c   Kook, Yeon H ^c   Park, Kyung H ^c   Oh, Eun T ^c   Griffin, Robert J ^b   Lim, Byung U ^b   Kim, Jin Seok ^d   Lee, Doo S ^e   Boothman, David A ^f   Loren, Melissa ^b   Song, Chang W ^b   Heon, Joo Park ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Inha University School of Medicine   (South Korea)

^d Sookmyung Women's University   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

A549 cells; Bioreductive drug; NQO1; Radiation; lapachone

Indexed keywords

BETA LAPACHONE; CASPASE 3; CYTOCHROME C; DICOUMAROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOREDUCTASE; PROTEIN P53; QUINONE OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DEATH; CELL KILLING; CELL SURVIVAL; CLONOGENESIS; ENZYME ACTIVITY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IRRADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 34548206759     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07397     Document Type: Article

References (42)

1. Begleiter A and Fourie J (2004). Induction of NQO1 in cancer cells. Methods Enzymol 382, 321-351.
2. Rauth AM, Goldberg Z, and Mirsa V (1997). DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 9, 339-349.
3. Ross D and Siegel D (2004). NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382, 115-144.
4. Siegel D, Beall H, Senekowitach C, Kasai M, Arai H, Gibson NW, and Ross D (1992). Bioreductive activation of mitomycin C by DT-diaphorase. Biol Chem 31, 7879-7885.
5. Robertwon N, Stratford IJ, Houlbrook S, Carmichael J, and Adams GE (1992). The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol 44, 409-412.
6. Brown JM (1994). The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 59, 5863-5870.
7. Loadman PM, Bibby MC, and Phillips RM (2002). Pharmacological approach towards the development of indolequinone bioreductive drugs used on the clinically inactive agent EO9. Br J Pharmacol 137, 701-709.
8. Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, and Ross D (2001). Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61, 1509-1516.
9. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, and Boothman DA (2001). β-Lapachone - induced apoptosis in human prostate cancer cells: involvement of Nqo/xip3. Exp Cell Res 267, 95-106.
10. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, and Boothman DA (2000). NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275, 5416-5424.
11. Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, Froelich CJ, and Boothman DA (2000). Activation of cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone mediated apoptosis. Exp Cell Res 255, 144-155.
12. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, and Boothman DA (2001). Calcium is a key signaling molecule in beta-lapachone medicated cell death. J Biol Chem 276, 19150-19159.
13. Park HJ, Ahn KJ, Ahn SD, Choi E, Lee SW, Williams B, Kim EJ, Griffin R, Bey EA, Bornmann WG, et al. (2005). Susceptibility of cancer cells to β-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys 61, 212-219.
14. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, and Lewis AD (1996). Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88, 259-269.
15. Hodnick WF and Satorelli AC (1993). Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res 53, 4907-4912.
16. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, and Bello J (1997). DT-diaphorase and cytochrome b5 reductase in human lung and breast tumors. Br J Cancer 76, 923-929.
17. Siegel D, Franklin WA, and Ross D (1998). Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4, 2065-2070.
18. Belinsky M and Jaiswal AK (1993). NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12, 103-117.
19. Cresteil T and Jaiswal AK (1991). High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42, 1021-1027.
20. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, and Ross D (1995). NAD(P)H:quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48, 499-504.
21. Li Y, Sun X, LaMont JT, Pardee AB, and Li CJ (2003). Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 100, 2674-2678.
22. Li CJ, Li YZ, Pinto AV, and Pardee AB (1999). Potent inhibition of tumor survival in vivo by beta-lapachone plus Taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 96, 13369-13374.
23. Pardee AB, Li YZ, and Li C (2002). Cancer therapy with β-lapachone. Curr Cancer Drug Targets 2, 227-242.
24. Boothman DA, Trask DK, and Pardee AB (1989). Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase. Cancer Res 49, 605-612.
25. Boothman DA, Greer A, and Pardee AB (1987). Potentiation of halo-genated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihyrdro-2,2-dimethyl-2H-naptho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 47, 5361-5366.
26. Boothman DA and Pardee AB (1989). Inhibition of radiation-induced neoplastic transformation by beta-lapachone. Proc Natl Acad Sci USA 86, 4963-4967.
27. Suzuki M, Amano M, Choi J, Park HJ, Williams B, Ono K, and Song CW (2006). Synergistic effects of radiation and β-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 165, 525-531.
28. Park HJ, Choi EK, Choi J, Ahn K, Kim EJ, Ji IM, Kook YH, Ahn S, Williams B, Griffin RJ, et al. (2005). Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of β-lapachone. Clin Cancer Res 11, 8866-8871.
29. Bentle MS, Reinicke KE, Bery EA, Spitz DR, and Boothman DA (2006). Calcium-dependent modulation of poly(ADP-ribose)polymerase-1 alters cellular metabolisms and DNA repair. J Biol Chem 281, 33684-33696.
30. Shapiro GI, Supko JG, Ryan DP, Appelman L, Berkenblit A, Craig AR, Jones D, Yagovane D, Li C, and Eder J (2005). Phase I trial of ARQ 501, an activated checkpoint therapy (ACT) agent, in patients with advanced solid tumors. J Clin Oncol 23 NO165 (June Suppl) Abstract No: 3042.
31. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998). DNA double-strand breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-5868.
32. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, and Tofilon PJ (2004). Enhanced radiation-induced cell killing and prolongation of H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64, 316-321.
33. Lowndes NF and Toh GW (2005). DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 15, R99-R102.
34. Park C, Hong S, Jin S, Kim N, Cho K, Choen J, Ahn J, Yang J, and Park R (2004). TRAIL-mediated apoptosis in human liver cells. Cancer Res Treat 35, 341-348.
35. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, and Strebhardt K (2002). RNA effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94, 1863-1877.
36. Zhang M, Zhang X, Bai C, Chen J, and Wei MQ (2004). Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 25, 61-67.
37. Park HJ, Lyon JC, Ohtsubo T, and Song CW (2000). Cell cycle progression and apoptosis after irradiation in an acidic environment. Cell Death Differ 7, 729-738.
38. Prochaska HJ and Santamaria AB (1988). Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 169, 328-336.
39. 2-phase arrest caused by ionizing radiation. Radiat Res 159, 86-93.
40. Dehn DL, Siegel D, Swann E, Moody CJ, and Ross D (2003). Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanisms-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. Mol Pharmacol 64, 714-720.
41. Tagliarino C, Pink JJ, and Boothman DA (2001). Calpains and apoptosis. Korean Biol Sci 5, 267-274.
42. Asher G, Lotem J, Sachs L, Kahana C, and Shaul Y (2002). Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. PNAS 99, 13125-13130.